Advertisement
UK markets close in 3 hours 54 minutes
  • FTSE 100

    8,083.39
    +38.58 (+0.48%)
     
  • FTSE 250

    19,799.65
    -0.07 (-0.00%)
     
  • AIM

    754.81
    -0.06 (-0.01%)
     
  • GBP/EUR

    1.1637
    +0.0010 (+0.08%)
     
  • GBP/USD

    1.2436
    -0.0016 (-0.13%)
     
  • Bitcoin GBP

    53,525.02
    +387.14 (+0.73%)
     
  • CMC Crypto 200

    1,434.32
    +10.22 (+0.72%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    82.81
    -0.55 (-0.66%)
     
  • GOLD FUTURES

    2,328.60
    -13.50 (-0.58%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,184.67
    +47.02 (+0.26%)
     
  • CAC 40

    8,132.51
    +26.73 (+0.33%)
     

A Performance Review and Analysts’ Ratings for Celgene in May

A Performance Review and Analysts’ Ratings for Celgene in May

In 1Q18, Celgene’s (CELG) Idhifa generated revenue of $14 million. Celgene and bluebird bio will commercialize the drug in the US market and share 50% of US expenditure and profits. Of the 31 analysts tracking Celgene (CELG) in May, seven analysts have recommended “strong buys,” while nine have recommended “buys” on its stock.